C. Dec Timothy's most recent trade in Supernus Pharmaceuticals Inc was a trade of 2,000 Common Stock done . Disclosure was reported to the exchange on March 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,000 | 12,898 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,000 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,800 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 1,800 | 13,636 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.06 per share. | 10 Mar 2025 | 1,062 | 11,836 (0%) | 0% | 32.1 | 34,048 | Common Stock |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.06 per share. | 10 Mar 2025 | 955 | 12,681 (0%) | 0% | 32.1 | 30,617 | Common Stock |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.05 per share. | 05 Mar 2025 | 1,587 | 12,228 (0%) | 0% | 33.0 | 52,450 | Common Stock |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.05 per share. | 05 Mar 2025 | 1,330 | 10,898 (0%) | 0% | 33.1 | 43,957 | Common Stock |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.05 per share. | 05 Mar 2025 | 276 | 13,815 (0%) | 0% | 33.1 | 9,122 | Common Stock |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 2,000 | 2,000 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 1,800 | 1,800 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2025 | 3,000 | 9,000 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2025 | 3,000 | 11,591 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2025 | 2,500 | 14,091 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2025 | 2,500 | 5,000 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2025 | 500 | 500 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2025 | 500 | 8,591 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 4,500 | 4,500 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | C. Dec Timothy | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 2,500 | 8,504 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Dec C. Timothy | Senior Vice-President & CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Feb 2024 | 2,500 | 7,500 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | C. Timothy Dec | Senior Vice-President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.06 per share. | 23 Feb 2024 | 1,314 | 7,190 (0%) | 0% | 29.1 | 38,185 | Common Stock |
| Supernus Pharmaceuticals Inc | Timothy Dec C. | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 50,000 | 50,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | C. Timothy Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 12,000 | 12,000 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Dec C. Timothy | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 500 | 6,004 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | C. Dec Timothy | Senior Vice-President & CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2024 | 500 | 1,000 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 1,500 | 3,359 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 1,500 | 0 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.47 per share. | 11 May 2023 | 709 | 2,650 (0%) | 0% | 36.5 | 25,857 | Common Stock |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 1,500 | 1,500 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 1,500 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 1,500 | 2,841 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.65 per share. | 14 Mar 2023 | 789 | 2,052 (0%) | 0% | 38.7 | 30,495 | Common Stock |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2023 | 500 | 1,500 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 500 | 1,341 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.57 per share. | 22 Feb 2023 | 193 | 1,148 (0%) | 0% | 38.6 | 7,444 | Common Stock |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 1,500 | 1,500 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Timothy C. Dec | Senior Vice-President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2021 | 85,000 | 85,000 | - | - | Employee Stock Option (Right to Buy) | |
| Opgen Inc | Timothy C. Dec | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2021 | 583 | 584 | - | - | Restricted Stock Units | |
| Opgen Inc | Timothy C. Dec | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2021 | 583 | 1,509 (0%) | 0% | 0 | Common Stock | |
| Opgen Inc | Timothy C. Dec | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 42,500 | 42,500 | - | - | Stock Option Award | |
| Opgen Inc | Timothy C. Dec | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2021 | 42,500 | 42,500 | - | - | Restricted Stock Award | |
| Opgen Inc | Timothy C. Dec | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 210,000 | 210,000 | - | - | Stock Option Award |